Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ENPP2 | Q13822 | 3/20 | 0.54 |
| ▸ | ATXN2 | Q99700 | 3/20 | 0.54 |
| ▸ | MEN1 | O00255 | 2/20 | 0.51 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.51 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.51 |
| ▸ | SMN1; SMN2 | Q16637 | 3/20 | 0.50 |
| ▸ | NPC1 | O15118 | 2/20 | 0.50 |
| ▸ | RAB9A | P51151 | 2/20 | 0.50 |
| ▸ | HTR2C | P28335 | 1/20 | 0.49 |
| ▸ | CYP2C19 | P33261 | 2/20 | 0.48 |
| ▸ | TACR1 | P25103 | 1/20 | 0.46 |
| ▸ | ACACB | O00763 | 1/20 | 0.45 |
| ▸ | TSHR | P16473 | 2/20 | 0.45 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.45 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.45 |
| ▸ | GAA | P10253 | 1/20 | 0.45 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.45 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.44 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.44 |
| ▸ | HIF1A | Q16665 | 1/20 | 0.44 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL30741614 | 0.92 | ENPP2 (0.49) | ENPP2ATXN2MEN1KMT2ANPSR1 | |
| SCHEMBL14249585 | 0.91 | ENPP2 (0.56) | ENPP2ATXN2MEN1KMT2ANPSR1 | |
| Hydrochloric Acid SCHEMBL14249583 | 0.90 | ENPP2 (0.55) | ENPP2ATXN2MEN1KMT2ANPSR1 | |
| SCHEMBL2727354 | 0.89 | CYP3A4 (0.58) | ENPP2ATXN2MEN1KMT2ANPSR1 | |
| SCHEMBL30484110 | 0.88 | MEN1 (0.57) | ENPP2ATXN2MEN1KMT2ANPSR1 | |
| Hydrochloric Acid SCHEMBL16678836 | 0.87 | CYP3A4 (0.57) | ENPP2ATXN2MEN1KMT2ANPSR1 | |
| Hydrochloric Acid SCHEMBL30121235 | 0.86 | MEN1 (0.56) | ENPP2ATXN2MEN1KMT2ANPSR1 | |
| SCHEMBL20739720 | 0.86 | ENPP2 (0.54) | ENPP2ATXN2MEN1KMT2ANPSR1 | |
| SCHEMBL10153538 | 0.86 | MEN1 (0.54) | ENPP2ATXN2MEN1KMT2ANPSR1 | |
| SCHEMBL16144658 | 0.84 | CYP3A4 (0.50) | ENPP2ATXN2MEN1KMT2ANPSR1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 33 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20260085066-A1 | LEUCINE RICH REPEAT KINASE 2 (LRRK2) DEGRADING COMPOUNDS AND ASSOCIATED METHODS OF USE | ARVINAS OPERATIONS INC (US) | 2026-03-26 | — | — | US | disclosed |
| CN-121574128-A | Pyrimidine-hydroxamic acid compounds and uses thereof | 华东理工大学 | 2026-02-27 | — | — | CN | disclosed |
| US-12559506-B2 | Indazole based compounds and associated methods of use | ARVINAS OPERATIONS, INC. (US) | 2026-02-24 | — | — | US | disclosed |
| US-12358898-B2 | Pyrimidine derivative, method for preparing same and use thereof in medicine | ZHEJIANG HISUN PHARMACEUTICAL CO., LTD. (CN) | 2025-07-15 | — | — | US | disclosed |
| US-20250171461-A1 | STIMULATOR OF INTERFERON GENES (STING) MODULATORS, AND COMPOSITIONS AND METHODS THEREOF | GEODE THERAPEUTICS INC (US) | 2025-05-29 | — | — | US | disclosed |
| US-20250002473-A1 | QUINOXALINE DERIVED SULFONAMIDES WITH EGFR DEGRADATION ACTIVITIES AND THEIR USES THEREOF | ACCUTAR BIOTECHNOLOGY INC. (US) | 2025-01-02 | — | — | US | disclosed |
| EP-4482839-A2 | STIMULATOR OF INTERFERON GENES (STING) MODULATORS, AND COMPOSITIONS AND METHODS THEREOF | Geode Therapeutics Inc. (US) | 2025-01-01 | — | — | EP | disclosed |
| WO-2024259216-A1 | QUINOXALINE DERIVED SULFONAMIDES WITH EGFR DEGRADATION ACTIVITIES AND THEIR USES THEREOF | ACCUTAR BIOTECHNOLOGY, INC. (US) | 2024-12-19 | — | — | WO | disclosed |
| CN-119110800-A | Modulators of interferon gene stimulating factor (STING), compositions and methods | 健道生物医药有限公司 | 2024-12-10 | — | — | CN | disclosed |
| US-20240360152-A1 | INDAZOLE BASED COMPOUNDS AND ASSOCIATED METHODS OF USE | ARVINAS OPERATIONS, INC. | 2024-10-31 | — | — | US | disclosed |
| US-20200207745-A1 | Pyrimidine Derivative, Method For Preparing Same And Use Thereof In Medicine | ZHEJIANG HISUN PHARMACEUTICAL CO., LTD. (CN) | 2020-07-02 | — | — | US | disclosed |
| US-10654836-B2 | Pyrimidine derivative, method for preparing same and use thereof in medicine | ZHEJIANG HISUN PHARMACEUTICAL CO., LTD. (CN) | 2020-05-19 | — | — | US | disclosed |
| US-20190161476-A1 | Pyrimidine Derivative, Method For Preparing Same And Use Thereof In Medicine | ZHEJIANG HISUN PHARMACEUTICAL CO., LTD. (CN) | 2019-05-30 | — | — | US | disclosed |
| EP-3459952-A1 | PYRIMIDINE DERIVATIVE, METHOD FOR PREPARING SAME AND USE THEREOF IN MEDICINE | Zhejiang Hisun Pharmaceutical Co., Ltd. (CN) | 2019-03-27 | — | — | EP | disclosed |
| WO-2017198221-A1 | PYRIMIDINE DERIVATIVE, METHOD FOR PREPARING SAME AND USE THEREOF IN MEDICINE | 浙江海正药业股份有限公司 | 2017-11-23 | — | — | WO | disclosed |
| US-8822688-B2 | Imidazo[1,2-a]pyridine derivative | ASTELLAS PHARMA INC. (JP) | 2014-09-02 | — | — | US | disclosed |
| US-8822688-B2 | Imidazo[1,2-a]pyridine derivative | ASTELLAS PHARMA INC. (JP) | 2014-09-02 | — | — | US | disclosed |
| US-20130053363-A1 | IMIDAZO[1,2-a]PYRIDINE DERIVATIVE | ASTELLAS PHARMA INC. (JP) | 2013-02-28 | — | — | US | disclosed |
| US-20130053363-A1 | IMIDAZO[1,2-a]PYRIDINE DERIVATIVE | ASTELLAS PHARMA INC. (JP) | 2013-02-28 | — | — | US | disclosed |
| WO-2011136192-A1 | IMIDAZO[1,2-a]PYRIDINE DERIVATIVE | アステラス製薬株式会社 (JP) | 2011-11-03 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (10 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20250171461-A1 | STIMULATOR OF INTERFERON GENES (STING) MODULATORS, AND COMPOSITIONS AND METHODS THEREOF | STING1, IRF3, CGAS | ENPP2 44/4885ATXN2 3331/4885MEN1 1561/4885 |
| US-20200207745-A1 | Pyrimidine Derivative, Method For Preparing Same And Use Thereof In Medicine | FGFR4, FGFR1, FGFR2 | ENPP2 3534/4885ATXN2 2072/4885MEN1 2284/4885 |
| US-12358898-B2 | Pyrimidine derivative, method for preparing same and use thereof in medicine | FGFR4, FGFR1, FGFR2 | ENPP2 3534/4885ATXN2 2072/4885MEN1 2284/4885 |
| US-20240360152-A1 | INDAZOLE BASED COMPOUNDS AND ASSOCIATED METHODS OF USE | LRRK2, CRBN, MDM2 | ENPP2 3378/4885ATXN2 153/4885MEN1 2327/4885 |
| US-10654836-B2 | Pyrimidine derivative, method for preparing same and use thereof in medicine | FGFR4, FGFR1, FGFR2 | ENPP2 3534/4885ATXN2 2072/4885MEN1 2284/4885 |
| US-12559506-B2 | Indazole based compounds and associated methods of use | LRRK2, CRBN, CLK2 | ENPP2 4511/4885ATXN2 209/4885MEN1 1946/4885 |
| US-20250002473-A1 | QUINOXALINE DERIVED SULFONAMIDES WITH EGFR DEGRADATION ACTIVITIES AND THEIR USES THEREOF | EGFR, ERBB2, ERBB4 | ENPP2 931/4885ATXN2 864/4885MEN1 3545/4885 |
| US-20190161476-A1 | Pyrimidine Derivative, Method For Preparing Same And Use Thereof In Medicine | FGFR4, FGFR1, FGFR2 | ENPP2 3534/4885ATXN2 2072/4885MEN1 2284/4885 |
| US-20130053363-A1 | IMIDAZO[1,2-a]PYRIDINE DERIVATIVE | PDE4B, PDE4A, PDE4C | ENPP2 2437/4885ATXN2 3247/4885MEN1 4281/4885 |
| US-20260085066-A1 | LEUCINE RICH REPEAT KINASE 2 (LRRK2) DEGRADING COMPOUNDS AND ASSOCIATED METHODS OF USE | LRRK2, PARK7, NEDD4 | ENPP2 3631/4885ATXN2 473/4885MEN1 4320/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.